Doxorubicin Anticancer Drug Monitoring by ds-DNA-Based Electrochemical Biosensor in Clinical Samples

Hassani Moghadam, Firouzeh; Taher, Mohammad A.; Karimi-Maleh, Hassan

doi:10.3390/mi12070808

Open AccessArticle

Doxorubicin Anticancer Drug Monitoring by ds-DNA-Based Electrochemical Biosensor in Clinical Samples

by

Firouzeh Hassani Moghadam

¹,

Mohammad A. Taher

^1,* and

Hassan Karimi-Maleh

^2,*

¹

Department of Chemistry, Shahid Bahonar University of Kerman, Kerman 7616913439, Iran

²

Laboratory of Nanotechnology, Department of Chemical Engineering and Energy, Quchan University of Technology, Quchan 9477177870, Iran

^*

Authors to whom correspondence should be addressed.

Micromachines 2021, 12(7), 808; https://doi.org/10.3390/mi12070808

Submission received: 9 June 2021 / Revised: 6 July 2021 / Accepted: 7 July 2021 / Published: 9 July 2021

(This article belongs to the Special Issue Feature Papers of Micromachines in Biology and Biomedicine 2021)

Download

Browse Figures

Versions Notes

Abstract

In this research, glassy carbon electrode (GCE) amplified with single-wall carbon nanotubes (SWCNTs) and ds-DNA was fabricated and utilized for voltammetric sensing of doxorubicin with a low detection limit. In this technique, the reduction in guanine signal of ds-DNA in the presence of doxorubicin (DOX) was chosen as an analytical factor. The molecular docking study revealed that the doxorubicin drug interacted with DNA through intercalation mode, which was in agreement with obtained experimental results. The DOX detection performance of ds-DNA/SWCNTs/GCE was assessed at a concentration range of 1.0 nM–20.0 µM. The detection limit was found to be 0.6 nM that was comparable and even better (in many cases) than that of previous electrochemical reported sensors. In the final step, the ds-DNA/SWCNTs/GCE showed powerful ability for determination of the DOX in injection samples with acceptable recovery data.

Keywords: docking investigation; doxorubicin; Sensor; modified biosensor

Share and Cite

MDPI and ACS Style

Hassani Moghadam, F.; Taher, M.A.; Karimi-Maleh, H. Doxorubicin Anticancer Drug Monitoring by ds-DNA-Based Electrochemical Biosensor in Clinical Samples. Micromachines 2021, 12, 808. https://doi.org/10.3390/mi12070808

AMA Style

Hassani Moghadam F, Taher MA, Karimi-Maleh H. Doxorubicin Anticancer Drug Monitoring by ds-DNA-Based Electrochemical Biosensor in Clinical Samples. Micromachines. 2021; 12(7):808. https://doi.org/10.3390/mi12070808

Chicago/Turabian Style

Hassani Moghadam, Firouzeh, Mohammad A. Taher, and Hassan Karimi-Maleh. 2021. "Doxorubicin Anticancer Drug Monitoring by ds-DNA-Based Electrochemical Biosensor in Clinical Samples" Micromachines 12, no. 7: 808. https://doi.org/10.3390/mi12070808

APA Style

Hassani Moghadam, F., Taher, M. A., & Karimi-Maleh, H. (2021). Doxorubicin Anticancer Drug Monitoring by ds-DNA-Based Electrochemical Biosensor in Clinical Samples. Micromachines, 12(7), 808. https://doi.org/10.3390/mi12070808

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Menu

Doxorubicin Anticancer Drug Monitoring by ds-DNA-Based Electrochemical Biosensor in Clinical Samples

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI